Switch to:
Also traded in: Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.12
FMS's Cash-to-Debt is ranked lower than
65% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 0.32 vs. FMS: 0.12 )
Ranked among companies with meaningful Cash-to-Debt only.
FMS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.06 Max: N/A
Current: 0.12
Equity-to-Asset 0.40
FMS's Equity-to-Asset is ranked lower than
61% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 0.46 vs. FMS: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
FMS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.4 Max: 0.5
Current: 0.4
0.35
0.5
Interest Coverage 5.85
FMS's Interest Coverage is ranked lower than
58% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.01 vs. FMS: 5.85 )
Ranked among companies with meaningful Interest Coverage only.
FMS' s Interest Coverage Range Over the Past 10 Years
Min: 3.95  Med: 4.88 Max: 6.3
Current: 5.85
3.95
6.3
Piotroski F-Score: 6
Altman Z-Score: 2.45
Beneish M-Score: -2.53
WACC vs ROIC
4.57%
9.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 14.76
FMS's Operating Margin % is ranked higher than
77% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 6.53 vs. FMS: 14.76 )
Ranked among companies with meaningful Operating Margin % only.
FMS' s Operating Margin % Range Over the Past 10 Years
Min: 13.9  Med: 15.69 Max: 16.51
Current: 14.76
13.9
16.51
Net Margin % 6.96
FMS's Net Margin % is ranked higher than
65% of the 219 Companies
in the Global Medical Care industry.

( Industry Median: 4.07 vs. FMS: 6.96 )
Ranked among companies with meaningful Net Margin % only.
FMS' s Net Margin % Range Over the Past 10 Years
Min: 6.15  Med: 7.65 Max: 8.6
Current: 6.96
6.15
8.6
ROE % 12.04
FMS's ROE % is ranked higher than
60% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 9.23 vs. FMS: 12.04 )
Ranked among companies with meaningful ROE % only.
FMS' s ROE % Range Over the Past 10 Years
Min: 11.29  Med: 13.36 Max: 14.68
Current: 12.04
11.29
14.68
ROA % 4.73
FMS's ROA % is ranked higher than
57% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 3.61 vs. FMS: 4.73 )
Ranked among companies with meaningful ROA % only.
FMS' s ROA % Range Over the Past 10 Years
Min: 4.31  Med: 5.3 Max: 6.22
Current: 4.73
4.31
6.22
ROC (Joel Greenblatt) % 41.03
FMS's ROC (Joel Greenblatt) % is ranked higher than
75% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 15.77 vs. FMS: 41.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FMS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 38.32  Med: 43.89 Max: 50.61
Current: 41.03
38.32
50.61
3-Year Revenue Growth Rate 16.30
FMS's 3-Year Revenue Growth Rate is ranked higher than
77% of the 182 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. FMS: 16.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FMS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.8  Med: 9.6 Max: 18.5
Current: 16.3
-17.8
18.5
3-Year EBITDA Growth Rate 14.70
FMS's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 7.80 vs. FMS: 14.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FMS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.4 Max: 59.5
Current: 14.7
0
59.5
3-Year EPS without NRI Growth Rate 13.00
FMS's 3-Year EPS without NRI Growth Rate is ranked higher than
58% of the 136 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. FMS: 13.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FMS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.8  Med: 12.95 Max: 62.7
Current: 13
-25.8
62.7
GuruFocus has detected 4 Warning Signs with Fresenius Medical Care AG & Co. KGaA $FMS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FMS's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FMS Guru Trades in Q1 2016

Manning & Napier Advisors, Inc 312,560 sh (unchged)
Keeley Asset Management Corp Sold Out
Jim Simons Sold Out
» More
Q2 2016

FMS Guru Trades in Q2 2016

Jim Simons 91,400 sh (New)
Manning & Napier Advisors, Inc 310,060 sh (-0.80%)
» More
Q3 2016

FMS Guru Trades in Q3 2016

Manning & Napier Advisors, Inc 338,470 sh (+9.16%)
Jim Simons 59,300 sh (-35.12%)
» More
Q4 2016

FMS Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 338,470 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FMS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FME3.Germany54.200.96

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:NYSE:HCA, NYSE:DVA, NYSE:UHS, OTCPK:IHHHF, OTCPK:RMSYF, OTCPK:FSNUY, NYSE:EVHC, NAS:WOOF, OTCPK:SKHCF, NYSE:MD, NYSE:HLS, NAS:ACHC, NYSE:CHE, OTCPK:LTGHY, NAS:LPNT, NAS:SCAI, NYSE:AMN, NYSE:THC, OTCPK:RHKJF, NAS:AMED » details
Traded in other countries:FMEN.Germany, FME.Italy, FMEN.Mexico, FME.Switzerland, 0H9X.UK, FMCQF.USA,
Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company, which is operating in both the field of dialysis products and dialysis services.

Based in Germany, Fresenius Medical Care is the largest global dialysis provider, with over 300,000 patients in North America, Europe, Latin America, and Asia. Fresenius operates over 2,270 clinics in North America, 700 in Europe, 360 in Asia-Pacific, and 230 in Latin America. Fresenius also sells dialysis machines and disposables, which represent nearly 20% of the company's revenue.

Ratios

vs
industry
vs
history
PE Ratio 20.98
FMS's PE Ratio is ranked higher than
69% of the 279 Companies
in the Global Medical Care industry.

( Industry Median: 28.41 vs. FMS: 20.98 )
Ranked among companies with meaningful PE Ratio only.
FMS' s PE Ratio Range Over the Past 10 Years
Min: 13.24  Med: 20.03 Max: 29.4
Current: 20.98
13.24
29.4
Forward PE Ratio 18.83
FMS's Forward PE Ratio is ranked higher than
60% of the 98 Companies
in the Global Medical Care industry.

( Industry Median: 19.01 vs. FMS: 18.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.98
FMS's PE Ratio without NRI is ranked higher than
66% of the 235 Companies
in the Global Medical Care industry.

( Industry Median: 27.34 vs. FMS: 20.98 )
Ranked among companies with meaningful PE Ratio without NRI only.
FMS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.24  Med: 20.03 Max: 29.4
Current: 20.98
13.24
29.4
Price-to-Owner-Earnings 21.57
FMS's Price-to-Owner-Earnings is ranked higher than
65% of the 97 Companies
in the Global Medical Care industry.

( Industry Median: 28.18 vs. FMS: 21.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
FMS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.4  Med: 21.6 Max: 36.52
Current: 21.57
12.4
36.52
PB Ratio 2.32
FMS's PB Ratio is ranked higher than
53% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 2.42 vs. FMS: 2.32 )
Ranked among companies with meaningful PB Ratio only.
FMS' s PB Ratio Range Over the Past 10 Years
Min: 1.64  Med: 2.49 Max: 3.01
Current: 2.32
1.64
3.01
PS Ratio 1.46
FMS's PS Ratio is ranked higher than
54% of the 270 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. FMS: 1.46 )
Ranked among companies with meaningful PS Ratio only.
FMS' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.5 Max: 1.89
Current: 1.46
1.02
1.89
Price-to-Free-Cash-Flow 23.29
FMS's Price-to-Free-Cash-Flow is ranked higher than
55% of the 134 Companies
in the Global Medical Care industry.

( Industry Median: 26.27 vs. FMS: 23.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
FMS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.05  Med: 24.13 Max: 53.67
Current: 23.29
14.05
53.67
Price-to-Operating-Cash-Flow 12.15
FMS's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 191 Companies
in the Global Medical Care industry.

( Industry Median: 14.39 vs. FMS: 12.15 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
FMS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.4  Med: 12.59 Max: 19.32
Current: 12.15
9.4
19.32
EV-to-EBIT 12.93
FMS's EV-to-EBIT is ranked higher than
76% of the 290 Companies
in the Global Medical Care industry.

( Industry Median: 19.26 vs. FMS: 12.93 )
Ranked among companies with meaningful EV-to-EBIT only.
FMS' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.3  Med: 12.6 Max: 16.8
Current: 12.93
7.3
16.8
EV-to-EBITDA 10.03
FMS's EV-to-EBITDA is ranked higher than
70% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 14.06 vs. FMS: 10.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
FMS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.8  Med: 10 Max: 13
Current: 10.03
5.8
13
PEG Ratio 2.19
FMS's PEG Ratio is ranked higher than
63% of the 90 Companies
in the Global Medical Care industry.

( Industry Median: 3.02 vs. FMS: 2.19 )
Ranked among companies with meaningful PEG Ratio only.
FMS' s PEG Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.3 Max: 36.43
Current: 2.19
1.07
36.43
Shiller PE Ratio 28.27
FMS's Shiller PE Ratio is ranked higher than
50% of the 46 Companies
in the Global Medical Care industry.

( Industry Median: 28.27 vs. FMS: 28.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
FMS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.67  Med: 28.4 Max: 44.54
Current: 28.27
20.67
44.54
Current Ratio 1.45
FMS's Current Ratio is ranked higher than
56% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. FMS: 1.45 )
Ranked among companies with meaningful Current Ratio only.
FMS' s Current Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.44 Max: 1.93
Current: 1.45
0.87
1.93
Quick Ratio 1.17
FMS's Quick Ratio is ranked higher than
50% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. FMS: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
FMS' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.15 Max: 1.61
Current: 1.17
0.7
1.61
Days Inventory 41.78
FMS's Days Inventory is ranked lower than
73% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 18.72 vs. FMS: 41.78 )
Ranked among companies with meaningful Days Inventory only.
FMS' s Days Inventory Range Over the Past 10 Years
Min: 33.91  Med: 37.82 Max: 41.78
Current: 41.78
33.91
41.78
Days Sales Outstanding 75.04
FMS's Days Sales Outstanding is ranked lower than
84% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 44.02 vs. FMS: 75.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
FMS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.64  Med: 76 Max: 83.04
Current: 75.04
71.64
83.04
Days Payable 19.08
FMS's Days Payable is ranked lower than
77% of the 143 Companies
in the Global Medical Care industry.

( Industry Median: 40.41 vs. FMS: 19.08 )
Ranked among companies with meaningful Days Payable only.
FMS' s Days Payable Range Over the Past 10 Years
Min: 17.84  Med: 19.24 Max: 28.3
Current: 19.08
17.84
28.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.08
FMS's Dividend Yield % is ranked lower than
67% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 1.65 vs. FMS: 1.08 )
Ranked among companies with meaningful Dividend Yield % only.
FMS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.32 Max: 2.07
Current: 1.08
0.93
2.07
Dividend Payout Ratio 0.22
FMS's Dividend Payout Ratio is ranked higher than
74% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 0.39 vs. FMS: 0.22 )
Ranked among companies with meaningful Dividend Payout Ratio only.
FMS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.22  Med: 0.27 Max: 0.31
Current: 0.22
0.22
0.31
3-Year Dividend Growth Rate 5.80
FMS's 3-Year Dividend Growth Rate is ranked lower than
67% of the 79 Companies
in the Global Medical Care industry.

( Industry Median: 10.10 vs. FMS: 5.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
FMS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 8
Current: 5.8
0
8
Forward Dividend Yield % 1.08
FMS's Forward Dividend Yield % is ranked lower than
68% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 1.84 vs. FMS: 1.08 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.37
FMS's 5-Year Yield-on-Cost % is ranked lower than
69% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 2.17 vs. FMS: 1.37 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
FMS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.18  Med: 1.67 Max: 2.62
Current: 1.37
1.18
2.62
3-Year Average Share Buyback Ratio -0.50
FMS's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 129 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. FMS: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FMS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.8  Med: -0.5 Max: 8
Current: -0.5
-11.8
8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.13
FMS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 137 Companies
in the Global Medical Care industry.

( Industry Median: 2.07 vs. FMS: 1.13 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
FMS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.92  Med: 1.26 Max: 1.72
Current: 1.13
0.92
1.72
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.53
FMS's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
71% of the 51 Companies
in the Global Medical Care industry.

( Industry Median: 1.83 vs. FMS: 1.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.97
FMS's Price-to-Median-PS-Value is ranked higher than
61% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 1.09 vs. FMS: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FMS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35  Med: 0.99 Max: 1.35
Current: 0.97
0.35
1.35
Price-to-Peter-Lynch-Fair-Value 2.54
FMS's Price-to-Peter-Lynch-Fair-Value is ranked lower than
53% of the 80 Companies
in the Global Medical Care industry.

( Industry Median: 2.23 vs. FMS: 2.54 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
FMS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.18  Med: 2.07 Max: 3.58
Current: 2.54
1.18
3.58
Earnings Yield (Greenblatt) % 7.73
FMS's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 332 Companies
in the Global Medical Care industry.

( Industry Median: 4.31 vs. FMS: 7.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FMS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.9  Med: 7.9 Max: 13.7
Current: 7.73
5.9
13.7
Forward Rate of Return (Yacktman) % 12.19
FMS's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 10.14 vs. FMS: 12.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
FMS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5  Med: 11.2 Max: 16.3
Current: 12.19
-5
16.3

More Statistics

Revenue (TTM) (Mil) $17,911
EPS (TTM) $ 2.04
Beta0.75
Short Percentage of Float0.15%
52-Week Range $38.05 - 47.52
Shares Outstanding (Mil)612.44

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,211 20,664 22,038
EPS ($) 3.13 3.83 26.84
EPS without NRI ($) 3.13 3.83 26.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.36%
Dividends per Share ($) 0.50 0.53 0.56
» More Articles for FMS

Headlines

Articles On GuruFocus.com
Another Attempt to Trumpet a Mistake Dec 19 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
Weekly 52-Week Highs Highlight: FMS, MTB, LO, LEN Apr 05 2015 
Weekly 3-Year Low Highlights: FMS, SNOW, KMDA, LAYN Jun 16 2014 
Weekly 52-Week Highs Highlight: MMP, AZO, BEAM, FMS Jan 26 2014 
Better Know a Company: Fresenius Medical Care (FMS) Apr 23 2013 
Warren Buffett Becomes Largest Owner of DaVita Mar 04 2013 
Warren Buffett’s Holding of DaVita Grows as Company Expands Jan 17 2013 
Buffett’s Berkshire Hathaway Buys Even More DaVita Shares Nov 29 2012 
Edward Owens Buys Walgreen Co., UCBH Holdings Inc., OSI Pharmaceuticals Inc., Sells Ventana Medical Aug 02 2007 

More From Other Websites
Fresenius (FMS) to Jointly Develop Acumen with Epic Systems Mar 20 2017
FMCNA’s Acumen Physician Solutions Division Unveils Acumen 2.0, Powered by Epic Mar 16 2017
Fresenius Medical Care AG & Co. KGaA :FMS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 10,... Mar 10 2017
Fresenius Medical Care and Humana Partner to Improve Health of Kidney Failure Patients Across the... Mar 09 2017
Fresenius Medical Care AG & Co. KGaA :FMS-US: Earnings Analysis: 2016 By the Numbers : February 28,... Feb 28 2017
FRESENIUS MEDICAL CARE AG & CO. KGAA Financials Feb 25 2017
Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat Feb 23 2017
Fresenius Medical Care misses 4Q revenue forecasts Feb 22 2017
Fresenius Medical Care misses 4Q revenue forecasts Feb 22 2017
Dialysis provider FMC settles with U.S. veterans department Jan 31 2017
SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Fresenius Medical Care AG & Co. KGAA,... Jan 26 2017
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Jan 26 2017
FRESENIUS MEDICAL NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In... Jan 26 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Fresenius Medical Care... Jan 26 2017
FMS LOSS NOTICE: Rosen Law Firm Continues to Investigate Securities Claims Against Fresenius Medical... Jan 26 2017
U.S. court issues injunction on assistance for dialysis patients Jan 26 2017
M&A-Hungry Nestle Looking at Baby Food Maker Mead Johnson Jan 23 2017
Fresenius Medical Care Uniquely Positioned to Transform Care for Kidney Failure Patients as Primary... Jan 19 2017
Lifshitz & Miller Law Firm Announces Investigation of DaVita Inc., First NBC Bank Holdings Company,... Jan 18 2017
CTSO: Poised For Strong 2017. Fresenius Deal A Win-Win-Win Jan 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)